Introduction To PK Rutgers iJOBS Seminar AAbrahamijobs.rutgers.edu/other/Introduction To PK...
Transcript of Introduction To PK Rutgers iJOBS Seminar AAbrahamijobs.rutgers.edu/other/Introduction To PK...
1
Introduction to Pharmacokinetics (PK)Anson K. Abraham, Ph.D.Associate Principal Scientist, PPDM-‐QP2Merck & Co. Inc., West Point, PA5-‐June-‐2017
2
Outline
• Definition & Relevance of Pharmacokinetics & Pharmacodynamics (PK/PD)
• Small v/s Large Molecules
• Fundamental Concepts of PK
• Q&A
3
What is Pharmacokinetics?
• Pharmacokinetics (PK)– What the body does to the drug
Parent DrugMetabolite
4
What is Pharmacokinetics?
• Pharmacokinetics (PK)– What the body does to the drug
Distribution
Parent DrugMetabolite
5
What is Pharmacokinetics?
• Pharmacokinetics (PK)– What the body does to the drug
Distribution
Elimination
Parent DrugMetabolite
ADME
6
PK Profiles Based on Route of Administration & Multiple Dosing
AUC: Area Under the Curve (measure of drug exposure)
7
What is Pharmacodynamics?
• Pharmacodynamics (PD)– What the drug does to the body
Parent DrugActive Metabolite
PD Effect of Proton Pump Inhibition
Rev Esp Enferm Dig. 2012 Jul;;104(7):367-78
http://annals.org/data/Journals/AIM/19857/6FF5.jpeg
PD Effect of Anti-Viral Drugs
Transporter Occupancy of Duloxetine
JPET, April 2012, 341 (1) 137-145
8
Has an Increased Understanding of PK/PD Helped?
Attrition of drug candidates
Nature Reviews Drug Discovery 2, 192-204 (March 2003) Nature Reviews Drug Discovery 14, 475–486 (2015)
Better understanding of PK/PD principles seems to have shifted the drug attrition profile
n = 198
9
Why is PK/PD Important? A Recent Example
• Selecting the right Drug and Dose in the right Population
Right Drug Right Dose & Regimen Right Population
10
Why is PK/PD Important? A Recent Example
• Selecting the right Drug and Dose in the right Population
Right Drug Right Dose & Regimen Right Population
11
Why is PK/PD Important? A Recent Example
• Selecting the right Drug and Dose in the right Population
Right Drug Right Dose & Regimen Right Population
Recent Example from PD-1 Inhibitors in Oncology
http://onlinelibrary.wiley.com/doi/10.1002/psp4.12140/full#psp412140-fig-0003Journal for ImmunoTherapy of Cancer, 2017, 5:43
12
Small vs Large Molecule
http://www.amgenbiosimilars.com/the-‐basics/the-‐power-‐of-‐biologics/
13
Small vs Large Molecule• For matters related to PK/PD, molecular size and structure matters!!!
Small Molecule:• Oral dosing route is generally preferred
• Half-life in body is typically in hours
• Additional PK considerations• Absorption characteristics from gut after oral dosing
• First-pass metabolism (liver)• Potential for drug-drug interactions
• Renal elimination• No immunogenicity concerns• Can access intra-cellular targets
Large Molecule:• IV/SC/IM dosing routes e.g. palivizumab (IM)
• Half-life in body is typically in days
• Additional PK considerations• Absorption characteristics from skin after SC dosing
• No first-pass metabolism (liver)• Minimal potential for drug-drug interactions
• Non-renal elimination mechanisms
• Immunogenicity concerns i.e. body can generate an immune response
• Primarily binds to extracellular targets
14
ADME -‐ Absorption
• Absorption is dependent on various physicochemical and physiological factors. The key parameters are – Solubility in the GIT– Permeability across the GI membrane
Parent Drug
AAPS J. 2012 Jun; 14(2): 244–251
15
ADME -‐ Absorption
• Passive Diffusion v/s Active Transport– Passive diffusion occurs based on a concentration gradient between
intestinal lumen and portal vein concentrations– Active transport of drug molecules is mediated through transporter
proteins with potential for capacity limitation (e.g. glucose & β-‐lactams)
Concentration
Initial Rate of
Absorption
Passive Diffusion
Active Transport
16
fg fhfa
Extent of Absorption (Small Molecules Oral Dosing)• Extent of absorption i.e. Bioavailability (F)
– Fraction absorbed from lumen (fa): Fraction of drug in the GI lumen that enters gut tissues
– Fraction absorbed from gut wall (fg): Fraction of drug in gut wall that enters the portal vein i.e. fraction escaping gut metabolism
– Hepatic fraction absorbed (fh): Fraction of drug in the portal vein that enters systemic circulation
– Hepatic Extraction Ratio (ER): Fraction of the drug that is extracted by the liver
𝐹 = 𝑓$ % 𝑓& % 𝑓' 𝑓' = (1 − 𝐸𝑅)
Nature Reviews Drug Discovery 2, 192-204 (March 2003)
F is relevant for SC or IM injections as well
17
Rate of Absorption (Small Molecules)
• Rate of absorption i.e. how fast the drug enters systemic circulation– Determines the time (tmax) to maximum concentration (Cmax)– For orally absorbed drugs, rate of absorption is generally described by
a first-‐order rate constant, ka. Units of ka is 1/time– Inverse relationship of ka with tmax
18
Question 1
• If the fraction of drug absorbed at each stage i.e. fa, fg, and fh is 50%, then what the bioavailability (F)?
– A: 2500.0%– B: 25.5%– C: 12.5%
𝐹 = 𝑓$ % 𝑓& % 𝑓'
19
Question 1 Solution
• If the fraction of drug absorbed at each stage i.e. fa, fg, and fh is 50%, then what the bioavailability (F)?
– C: 12.5%𝐹 = 𝑓$ % 𝑓& % 𝑓'
Explanation: F = 0.5 x 0.5 x 0.5 = 0.125 x 100 = 12.5%
• Drugs like vancomycin and gentamycin are polar with MWT >400 g/mole. These drugs have low F due to low fa
20
ADME -‐ Distribution
• Volume of distribution (V) of a drug is an apparent volume that correlates amount and concentration of drug in the body
• Typical physiological volumes include:
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =𝐴𝑚𝑜𝑢𝑛𝑡𝑉𝑜𝑙𝑢𝑚𝑒
21
Why is “V” an Apparent Volume of Distribution?
• Reported volumes greatly exceed physiological volumes
• Apparent “V” is determined by factors such as polarity, lipophilicity, and ionization state (pKa)
Rowland, M., Tozer, T. N., & Rowland, M. (2011). Clinical pharmacokinetics and pharmacodynamics: Concepts and applications. Philadelphia: Wolters Kluwer Health/Lippincott William & Wilkins.
22
Volume of Distribution (V or Vd)
• Volume of distribution is useful to calculate a loading dose
500mg
500 mL 1 mg/mL
Time
Concentration (C)
I.V. Bolus
Ctime=0 = Dose / V
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =𝐴𝑚𝑜𝑢𝑛𝑡𝑉𝑜𝑙𝑢𝑚𝑒
23
Volume of Distribution is Apparent
500mg
water water500 mL
ConcWater = 1 mg/mL;;
Thus V = 500 mL
𝑉𝑜𝑙𝑢𝑚𝑒 =𝐴𝑚𝑜𝑢𝑛𝑡
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
24
Volume of Distribution is Apparent
500mg
water water
water
octanol500mg 500 mL
500 mL
500 mL
ConcWater = 1 mg/mL;;
Thus V = 500 mL
water
octanol1:1
ConcWater = 0.5 mg/mL;;
Thus V = 1000 mL
𝑉𝑜𝑙𝑢𝑚𝑒 =𝐴𝑚𝑜𝑢𝑛𝑡
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
25
Volume of Distribution is Apparent
• Partitioning contributes to an increase in apparent volume of distribution– Lipophilic drugs that distribute extensively into tissues e.g. diazepam
(V = 168 L)– Vmay approach physiological volumes e.g. monoclonal antibodies at
high doses
500mg
water water
water
octanol500mg 500 mL
500 mL
500 mL
ConcWater = 1 mg/mL;;
Thus V = 500 mL
water
octanol
1 (water):9 (octanol)
ConcWater = 0.1 mg/mL;;
Thus V = 5000 mL
1Gibaldi, M. 1984 "Biopharmaceutics and Clinical Pharmacokinetics", 3rd ed., Lea & Febiger, Chapter 12, page 214
26
PK Models – One or More Compartments
• Poly-‐exponential PK indicates distribution phenomenon (non-‐specific or target-‐related)
• A poly-‐exponential PK curve will required two or more compartments for adequate characterization of data
Time
Log Concentration (C)
Mono-exponential
Time
Log Concentration (C)
Poly-exponential
27
Question 2
• Which drug has a larger volume of distribution?
Drug A
Drug B
28
Question 2: Solution
• Which drug has a larger volume of distribution?– Answer: Drug B
Drug A
Drug B
For any drug, a large apparent V is not necessarily a disadvantage. The absolute value of V is indicative of where the drug is distributed as well as physicochemical properties of the drug
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =𝐴𝑚𝑜𝑢𝑛𝑡𝑉𝑜𝑙𝑢𝑚𝑒
29
ADME – Metabolism & Elimination
•Hepatic & Gut Metabolism– CYP, UGT, etc… enzymes
• Renal Elimination• Various terms referring to Elimination– Clearance i.e. CL (Units: volume/time)
§ For an organ, the maximal clearance is equal to blow flow to that organ» Liver blood flow = 1.5 L/min» Kidney blood flow = 1.2 L/min» Glomerular Filtration Rate i.e. GFR = 0.1 L/min
– Elimination Rate Constant i.e. kel (Units: 1/time)
– Elimination half-‐life i.e. thalf (Units: time)
30
Clearance (CL)
• Drug CL is the volume that is cleared of a drug per unit of time
. . . .. .
.......
Volume
Concentration. . . .
. ..
...
t = 0
...
e.g: t = 1 sec
CL = 3 drops/sec
. . . .. . .
..
. ...
CL = 6 drops/sec
e.g: t = 1 sec
31
. . . .. .
.......
Volume
Concentration. . . .
. ..
...
t = 0
...
e.g: t = 1 sec
CL = 3 drops/sec
. . . .. . .
..
. ...
CL = 6 drops/sec
e.g: t = 1 sec
..
..
....
. ... ...
Clearance at Steady-‐State(CL)• At steady-‐state, Rate In = Rate Out
• For IV infusions, the dosing rate can be calculated using CL and required steady state concentration
. . .
𝐼𝑛𝑓𝑢𝑠𝑖𝑜𝑛?$@A = 𝐶𝐿 % 𝐶𝑜𝑛𝑐CC
32
Total Clearance
Total CL is representative of the sum of all clearance mechanisms and organs
CL = CLgut + CLliver + CLkidney
Time
Concentration (C)
Concentration
Rate GFR
Concentration
Rate Secretion by Active Transport
Concentration
Rate Metabolism by CYPs
33
Impact of Clearance on PK
• CL is an important determinant of drug exposure (AUC)
𝐶𝐿 = 𝐷𝑜𝑠𝑒. 𝐹𝐴𝑈𝐶0−inf
, 𝑤ℎ𝑒𝑟𝑒 𝐹 = 1 𝑓𝑜𝑟 𝐼𝑉
Low CL
High CL
Minimal Efficacious Concentration
Maximum Safe Concentration
Ideal CL
34
Metabolism
• Primarily impacts small molecules• Four common type of reactions include:
– Oxidation: Majorly mediated through cytochrome P450 (CYP) enzymes– Hydrolysis: Aspirin to salicylic acid and acetic acid– Reduction– Conjugation: Phase 2 reactions such as glucuronidation
• Metabolites are typically more polar and water soluble. Hence, lower reabsorption
• In some cases, metabolites may also be active– Prodrug: Codeine to morphine
• Characterizing metabolic profile of drugs is important to predict drug-‐drug interactions
35
Question 3a
• Two drugs (A & B) are co-‐administered simultaneously. Drug A is known to induce the CYP3A4 enzyme. Drug B is primarily metabolized by CYP3A4 to an inactive metabolite. What is the impact on the PK (exposure) for both drugs compared to when these drugs are administered alone?A. AUC of Drug B is lowerB. AUC of both drugs A & B is lowerC. No impact on AUCD. AUC of Drug B is higher
36
Question 3a: Solution
• Two drugs (A & B) are co-‐administered simultaneously. Drug A is known to induce the CYP3A4 enzyme. Drug B is primarily metabolized by CYP3A4 to an inactive metabolite. What is the impact on the PK (exposure) for both drugs compared to when these drugs are administered alone?A. AUC of Drug B is lower (efficacy may be compromised)B. AUC of both drugs A & B is lowerC. No impact on AUCD. AUC of Drug B is higher
Drug-drug interactions (DDI) are a major concern for drugs that are eliminated via the metabolic pathway. Enzyme induction may result in sub-therapeutic doses of drug.
37
Question 3b
• Two drugs (A & B) are co-‐administered simultaneously. Drug A is known to inhibit the CYP3A4 enzyme. Drug B is primarily metabolized by CYP3A4 to an inactive metabolite. What is the impact on the PK (exposure) for both drugs compared to when these drugs are administered alone?A. AUC of Drug B is lowerB. AUC of both drugs A & B is lowerC. No impact on AUCD. AUC of Drug B is higher
38
Question 3b: Solution
• Two drugs (A & B) are co-‐administered simultaneously. Drug A is known to inhibit the CYP3A4 enzyme. Drug B is primarily metabolized by CYP3A4 to an inactive metabolite. What is the impact on the PK (exposure) for both drugs compared to when these drugs are administered alone?A. AUC of Drug B is lower B. AUC of both drugs A & B is lowerC. No impact on AUCD. AUC of Drug B is higher (potential safety concern)
Drug-drug interactions (DDI) are a major concern for drugs that are eliminated via the metabolic pathway. This is especially true for drugs with a narrow therapeutic index.
An ideal drug candidate would have multiple elimination pathways, such that inhibiting any one pathway does not significantly impact exposures.
39
Source: Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and Elimination, Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e
Citation: Brunton LL, Chabner BA, Knollmann BC. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 12e; 2011 Available at: http://accesspharmacy.mhmedical.com/content.aspx?bookid=1613§ionid=102157226 Accessed: June 02, 2017
Copyright © 2017 McGraw-Hill Education. All rights reserved
The interrelationship of the absorption, distribution, binding, metabolism, and excretion of a drug and its concentration at its sites of action. Possibledistribution and binding of metabolites in relation to their potential actions at receptors are not depicted.
PK in a Nutshell – Use Free Drug Concentrations
40
PK Analysis -‐ NCA
• Non-‐Compartmental Analysis– Slope (k)– Height (Cmax)– Area Under the Curve (AUC)
1
10
100
0 10 20 30 40 50
Plasma Concentration
Time
C(tn)
Cmax
AUC0-inf = AUC(0-tn) + C(tn)’/k
AUC (0-tn)
tn
slope = - k
AUC(tn-inf)Ideally <25% extrapolated area
𝐶𝐿 = 𝐷𝑜𝑠𝑒. 𝐹𝐴𝑈𝐶0−inf
, 𝑤ℎ𝑒𝑟𝑒 𝐹 = 1 𝑓𝑜𝑟 𝐼𝑉
𝐹 =𝐴𝑈𝐶𝑝𝑜𝐷𝑜𝑠𝑒KL
%𝐷𝑜𝑠𝑒𝑖𝑣𝐴𝑈𝐶NO
t1/2 = 0.693/kElimination half-life
41
PK Analysis – Compartmental Evaluation
ka kelDose Comp.1
One compartment body model with first order absorption (e.g. Oral dose)
𝐶K =𝐷𝑜𝑠𝑒 % 𝐹 % 𝑘$𝑉 % (𝑘$ − 𝑘AQ)
(𝑒RSTU%@ − 𝑒RSV%@)
Goal: Estimate model parameters using non-linear regression
42
Final Questions
• Assume same IV dose for drugs A & B• Q1: Which drug has higher CL?
1. A 2. B3. A = B
AUC = 10 AUC = 10
43
Final Questions
• Assume same IV dose for drugs A & B• Q1: Which drug has higher CL?
1. A 2. B3. A = B
AUC = 10 AUC = 10
𝐶𝐿 = 𝐷𝑜𝑠𝑒. 𝐹𝐴𝑈𝐶0−inf
, 𝑤ℎ𝑒𝑟𝑒 𝐹 = 1 𝑓𝑜𝑟 𝐼𝑉
44
Final Questions
• Assume same dose for drugs A & B • CL = 1.5 L/min• Q2: Which compound has greater tissue distribution?
1. A 2. B
AUC = 10 AUC = 10
45
Final Questions
• Assume same dose for drugs A & B • CL = 1.5 L/min• Q2: Which compound has greater tissue distribution?
1. A 2. B
AUC = 10 AUC = 10
46
Final Questions
• Assume same dose for drugs A & B • CL = 1.5 L/min• Q3: Is glomerular filtration the sole mechanism of elimination?
1. Yes2. No
AUC = 10 AUC = 10
Hint: GFR is ~0.1 L/min
47
Final Questions
• Assume same dose for drugs A & B • CL = 1.5 L/min• Q3: Is glomerular filtration the sole mechanism of elimination?
1. Yes2. No
AUC = 10 AUC = 10
Hepatic metabolism could be a major and sole elimination pathway as well.
48
Model-‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development
Clinical Pharmacology & TherapeuticsVolume 93, Issue 6, pages 502-514, 14 MAR 2013 DOI: 10.1038/clpt.2013.54http://onlinelibrary.wiley.com/doi/10.1038/clpt.2013.54/full#cptclpt201354-fig-0001
49
Examples Where Model-‐Based Analysis Has Helped Speed Up Drug Development
49
Clinical Pharmacology & TherapeuticsVolume 93, Issue 6, pages 502-‐514, 14 MAR 2013
50
Label – Sections Informed by PKPD Information
FULL PRESCRIBING INFORMATION: CONTENTS* WARNING – LIFE-THREATENING HEMATOLOGICAL ADVERSE REACTIONS 1 INDICATIONS AND USAGE
1.1 Thrombotic Stroke 1.2 Coronary Stenting
2 DOSAGE AND ADMINISTRATION 2.1 Thrombotic Stroke 2.2 Coronary Stenting 2.3 Renally Impaired Patients
3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS
5.1 Hematological Adverse Reactions 5.2 Monitoring for Hematological Adverse Reactions 5.3 Anticoagulant Drugs 5.4 Bleeding Precautions 5.5 Monitoring: Liver Function Tests
6 ADVERSE REACTIONS 6.1 Clinical Studies Experience 6.2 Postmarketing Experience
7 DRUG INTERACTIONS 7.1 Anticoagulant Drugs 7.2 Phenytoin 7.3 Antipyrine and Other Drugs Metabolized Hepatically 7.4 Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs 7.5 Cimetidine 7.6 Theophylline 7.7 Propranolol 7.8 Antacids 7.9 Digoxin 7.10 Phenobarbital 7.11 Other Concomitant Drug Therapy 7.12 Food Interaction
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Renal Impairment 8.7 Hepatic Impairment
10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 14.1 Thrombotic Stroke 14.2 Coronary Stenting 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION
17.1 Importance of Monitoring 17.2 Bleeding 17.3 Hematological Adverse Reactions 17.4 FDA-Approved Patient Labeling
*Sections or subsections omitted from the full prescribing information are not listed.
51
PK Optimization in Drug Development
Nature Reviews Drug Discovery 2, 192-‐204 (March 2003)
52
Thank You!!!